This site uses cookies to improve your experience.

We use necessary cookies to make our site work. We would also like to set optional analytics cookies to help us improve our site by anonymously collecting and reporting information on how you use it. For more information on how these cookies work, please see our Cookie policy.

Variant Bio

Vision Fund investment portfolio company Variant Bio's logo

Variant Bio is developing therapies to improve global health by studying human genetics.

Leadership
Andrew Farnum
Fund
SVF2
Status
Private
Sector
Health Tech
Region
Americas
Insights
Feature
Variant Bio: Charting a New Path in Genomic Drug Discovery

How Variant Bio is mapping highly differentiated data to accelerate drug development